Latest news
Two Years of Progress in Grade 2 IDH-Mutant Glioma – Servier Pharmaceuticals - OncodailyOncodaily · Sat, 08 Aug 2026 18:35:41 GMTVorasidenib improves response to subsequent chemoradiation in a genetically engineered mouse model of IDH-mutant glioma - Science | AAASScience | AAAS · Wed, 05 Aug 2026 18:30:42 GMTUpdated Safusidenib Data Show Durable Responses in Grade 2 IDH1-Mutant Glioma - OncLiveOncLive · Mon, 27 Jul 2026 13:07:10 GMT